The CML Advocates Network is both a virtual network and internet platform for patient organisations supporting patients and relatives affected by Chronic Myeloid Leukaemia (CML). Launched in 2007 with 4 founding member groups, it has now grown to a network of 131 leukaemia patient groups from 96 countries on all continents, offering support by sharing of best practice, information and advice for CML patient representatives.

Read more

On the iCMLf Knowledge Centre - an interactive online resource developed by International CML experts from the iCMLf, there is a module on pediatric CML.

Chaired by Professor Meinolf Suttorp and Professor Nirmalya Roy Moulik, this module outlines a comprehensive review of the treatment of pediatric CML. You can acces the presentations here that cover all relevant aspects of pediatric CML:

1. Difference between adult and pediatric CML (Dr Deepam Pushpam, India)
2. Predisposition and genetic factors in pediatric CML (Professor Markus Metzler, Germany)
3. Management of pediatric CML in the resource-restrained setting (Dr Nirmalya Roy Moulik India)
4. Treatment recommendations for pediatric CML - Chronic phase (Professor Frédéric Millot, France)
5. Treatment recommendations in pediatric CML - Blast phase (Dr Stephanie Sembill, Germany)
6. Treatment-free remission in pediatric CML (Professor Nobuko Hijiya, USA)
7. Tyrosine kinase inhibitor toxicity in pediatric CML (Dr Maaike Luesink, The Netherlands)
8. Parenting in children with CML (Professor Meinolf Suttorp, Germany)
9. Impact of tyrosine kinase inhibitors on growth and endocrine function in children with CML
   (Professor Meinolf Suttorp, Germany)

Access additional modules on the iCMLf Knowledge Centre here.

Please see below for a selection of interesting articles on pediatric CML in peer-reviewed journals.

We are delighted to share the second case review in our series dedicated to the treatment of pediatric CML (pCML) in low and middle-income countries (LMICs) that highlights a challenging case from Brazil. Experts discuss treatment discontinuation in a child with CML who has not achieved a sustained deep molecular response.

Cases of Patients Treated in Countries With Limited Resources and Discussed by Experts of the International CML Foundation (iCMLf)—Case No. 2: Treatment-Free Remission After 9 Years of Imatinib Treatment Without Prior Achievement of Sustained Deep Molecular Response.
Michalowski, MB et al. Case Reports in Oncological Medicine, March 2025 – open access publication

This series of pediatric CML case reviews aims to provide a comprehensive discussion of challenging pCML cases from various perspectives to enhance knowledge and improve patient outcomes.

Other latest publications include:

• Management of children and adolescents with chronic myeloid leukemia in chronic-phase: International pediatric chronic myeloid leukemia expert panel recommendations
  Millot F et al. Leukemia, March 2025 (epub ahead of print)
• Therapeutic drug monitoring of imatinib in pediatric chronic myeloid leukemia: Data from a real-world setting
  Suttorp M et al. Br J Haematol, March 2025 (epub ahead of print) – open access publication
• Favorable outcomes of de novo advanced phases of pediatric chronic myeloid leukemia in the tyrosine kinase inhibitor era
  Yoshikawa T et al. Int J Hematol, March 2025 (epub ahead of print) – open access publication
• Distribution of BCR::ABL1 transcript types and response to therapy in pediatric patients with chronic myeloid leukemia
  Seiser E et al. J Mol Diagn, January 2025 (epub ahead of print)
• Optimizing diagnostic tools and outcomes evaluation for t(9;22)-positive leukemias in pediatric low middle-income country (LMIC) patients
  Bukhari SI et al. Cancer Invest, January 2025 (epub ahead of print)
• Growth retardation and adult height in pediatric patients with chronic-phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
  Shima H et al. Leukemia, December 2024 (epub ahead of print)
• Treatment-free remissions in children with chronic myeloid leukemia (CML): 
  A prospective study from the Tata Memorial Hospital (TMA) Pediatric CML (pCML) cohort
  Roy Moulik N et al. Am J Hematol, November 2024 (epub ahead of print) – open access publication
• Clinical characteristics and outcomes of CML in adolescents and young adults
  Al Rabi K et al. Clin Lymphoma Myeloma Leuk, Oct 2024
• A high proportion of germline variants in pediatric chronic myeloid leukemia in pediatric chronic myeloid leukemia
  Krumbhold M et al. Mol Cancer, Sept 2024 – open access publication
• CAR-T cells for the treatment of pediatric chronic myeloid leukemia in repeatedly relapsed lymphoid blast crisis
  Kramp LJ et al. Ann Hematol, Sept 2024 (epub ahead of print) – open access publication
• Low-level BCR::ABL1 transcript at diagnosis in childhood leukemia: A 10-year single institution study
  Cain LE et al. Genes Chromosomes Cancer, Sept 2024
  
• Cases of Patients Treated in Countries With Limited Resources and Discussed by Experts of the International CML Foundation (iCMLf) – Case No. 1: A Boy Presenting With Priapism and Loss of Vision
  Roy Moulik et al. Case Rep Oncol Med, July 2024 – open access publication
• Chronic myeloid leukemia in adolescents and young adults: Clinicopathological variables and outcomes
  Abdulla MA et al. Oncology, July 2024 (epub ahead of print) – open access publication
• Impact of tyrosine kinase inhibitors (TKIs) on growth in children and adolescents with chronic myeloid leukemia: A systematic review
  Katsarou D et al. Curr Pharm Des, July 2024 (epub ahead of print)
• Challenges in management of pediatric chronic myeloid leukemia (pCML) in the low-middle income countries (LMIC's): Insights from an International CML Foundation (iCMLf) Multi-National survey
  Roy Moulik N et al. Pediatr Hematol Oncol, May 2024

Search here for more publications on pediatric CML

• Management of children and adolescents with chronic myeloid leukemia in blast phase: International pediatric CML expert panel recommendations – Review
  (Sembill S et al. Leukemia, January 2023) (epub ahead of print) – open access publication
• Management of chronic myeloid leukemia in childen and adolescents:
  Recommendations from the Children's Oncology Group CML Working Group
  (Athale U et al. Pediatr Blood Cancer, September 2019) - open access publication
• Managing children with CML: Pediatric CML guidelines IBFM
  (Fuente J et al. Br J Haematology, July 2014)

See here for more general guidelines on the management of CML

• Childhood chronic myeloid leukemia treatment (PDQ): Health Professional Version - Review
  PDQ Pediatric Treatment Editorial Board, September 2024
  In: PDQ Cancer Information Summaries (Internet) Bethesada (MD) National Cancer Institute (US); 2002-.
• Impact of tyrosine kinase inhibitors (TKIs) on growth in children and adolescents with chronic myeloid leukemia:
  A systematic review
  Katsarou D et al. Curr Pharma Res, July 2024
• BCR/ABL positive chronic myeloid leukemia in children: Current treatment approach - Review
  Menger JM et al. Curr Oncol Rep, February 2024 (epub ahead of print)
• Chronic myeloid leukemia in children and adolescents - Review
  (Gotesman M et al. Adv Pediatr, August 2023)
• Recent progress in the management of pediatric chronic myeloid leukemia – Review
  (Shima H and Shimada H. Int J Hematol, December 2022) (epub ahead of print)
• Chronic myeloid leukemia in children: immune function and vaccinations
  (Suttorp M et al. J Clin Med, September 2021) - open access publication
• Management of pediatric leukemia (in French)
  (Héritier S et al. Soins Pediatr Peuric, May-June 201)
• Tyrosine kinase inhibitors and beyond for chronic myeloid leukemia in children
  (Phillips LN and Hijiya N. Pediatr Drugs, May 2021)
• Chronic myelogenous leukemia in childhood
  (Smith SM et al. Curr Oncol Rep, March 2021)
• Definition, epidemiology, pathophysiology, and essential criteria for diagnosis of pediatric chronic myeloid leukemia
  Suttorp M et al. Cancers(Basel), February 2021 - open access publication
• Features and outcomes of chronic myeloid leukemia at very young age:
  Data from the International Pediatric Registry
  (Meral Günes A et al. Pediatr Blood Cancer, January 2021)
• Horn of plenty: Value of the International registry fore pediatric chronic myeloid leukemia
  (Suttorp M et al. World J Clin Oncol, June 2020) - open access publication
• How I treat chronic myeloid leukemia in children and adolescents
  (Hijiya N and Suttorp M. Blood, May 2019) - open access publication
• Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions 
  (Hijiya N et al. Pediatr Clin North Am, February 2016)
• Chronic myeloid leukemia in children is a unique disease that requires a different approach 
  (Hijiya N et al. Blood, October 2015)

Our 'Clinical Case Discussion Forum' features a number of discussions on pediatric CML cases. If you are a physician treating pediatric CML patients, please join our forum and get in touch with other experts.

The latest postings on pediatric CML include:

• A 19 yo on asciminib as 4L, new updates
  • Last post: Acy Quixada
• pCML - relapse post allogeneic transplant
  • Last post: M.A. Durosinmi
• Non attainment of MMR in pediatric patients without TKD mutations - options?
  • Last post by Nobuko Hijiya
• Dual T315I mutation F359I mutation positive pediatric CML lymphoid blast crisis
  • Last post by Giuseppe Saglio
• 24 y female / CML-AP - 11 yr/3 TKI+ (T315I mut.) I treatment after ponatinb
  • Last post by Michael Deininger
• CML in younger patients in low socio-economic areas
  • Last post by Nasir Ahmad
• Challenging case - male 20 yrs old
  • Last post by Giuseppe Saglio
• Outcomes in children born to males on nilotinib
  • Last post by Jane Apperley
• 22 year old with no MMR after 3+ yrs on dasatinib
  • Last post by Timothy Hughes
• Ponatinib dose for pediatric patients
  • Last post by Nobuko Hijiya
• CML under 18 years old
  • Last post by Meinolf Suttorp
• 2nd transplant for 16 year old boy
  • last post by Timothy Hughes 

A number of clinical trials and research activities are currently ongoing to research pediatric CML.
Find more information here.